Emerging from the shadow of Vioxx.
Lindsley
Craig W
CW
Vanderbilt University Medical Center, RRB 804, Nashville, TN 37232-6600, USA.
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects / Q000737:chemistry; D052246:Cyclooxygenase 2 Inhibitors / Q000009:adverse effects / Q000737:chemistry; D017277:Drug Approval; D000077613:Etoricoxib; D006801:Humans; D007783:Lactones / Q000009:adverse effects / Q000737:chemistry*; D011725:Pyridines / Q000009:adverse effects / Q000737:chemistry*; D013450:Sulfones / Q000009:adverse effects / Q000737:chemistry*
D000894:Anti-Inflammatory Agents, Non-Steroidal; D052246:Cyclooxygenase 2 Inhibitors; D007783:Lactones; D011725:Pyridines; D013450:Sulfones; C116926:rofecoxib; D000077613:Etoricoxib